RENO, Nev. (PRWEB) January 07, 2019
Duncan Family Healthcare, a nurse-managed primary care and mental health clinic providing efficient, evidence-based, compassionate care to the Reno and Sparks region, announced today that it now offers transcranial magnetic stimulation (TMS) for the treatment of Major Depressive Disorder (MDD) — making it the first and only provider of TMS therapy in Reno, where mental health services are in high demand. According to Mental Health America’s most recent rankings, Nevada is ranked fifty-first in mental health services and availability.
Duncan Family Healthcare’s opening two years ago was one of the first brick-and-mortar nurse practitioner-run businesses in Reno and the state. Offering a unique approach to healthcare, with special attention to mental health and physical health needs, the practice combines the intricacies of medicine with the caring, comprehensive care of nursing to improve health. The most recent addition to its roster of mental health services is NeuroStar® Advanced Therapy TMS, which uses magnetic pulses to stimulate areas of the brain that are underactive in depression. NeuroStar Advanced Therapy offers doctors real-time feedback and delivers enhanced care with its precise and accurate targeting, providing reliable and consistent treatment.
“Nevada desperately needs increased access to mental health services, and I am especially passionate about bringing treatment options to my hometown. I have seen the success of NeuroStar Advanced Therapy in treating depression and I’m thrilled to bring this proven non-invasive, non-drug treatment option to Reno,” said Dr. Cameron Duncan, family nurse practitioner, psychiatric mental health nurse practitioner and founder of Duncan Family Healthcare. “We’ve treated about 35 patients to date with great results. Each person treated with NeuroStar responded positively and several were able to achieve complete remission from their depression.”
NeuroStar Advanced Therapy is widely covered by major insurance plans and is available by prescription. The treatment is typically administered daily in a doctor's office for four to six weeks, with treatment sessions performed in as little as just under 19 minutes.* Unlike electroconvulsive therapy (ECT), NeuroStar Advanced Therapy is non-invasive and allows patients to resume daily activities immediately following treatment sessions. It is also free from systemic side effects often associated with antidepressant medications.
In celebration of its new treatment offering, Duncan Family Healthcare will host an educational open house event on Thursday, January 10 from 5:30 p.m.– 7:30 p.m. at its Reno facility located at 6630 S. McCarran Blvd., Building A, Suite #A12. Duncan Family Healthcare is open Monday through Friday from 8 a.m. – 5 p.m. To learn more and schedule an appointment, visit http://www.duncanfamilyhealthcare.com.
About Duncan Family Healthcare
Duncan Family Healthcare is a nurse-managed primary care and mental health clinic providing efficient, evidence-based, compassionate care to the Reno/Sparks community. Its mission is to provide personalized, high-quality care to improve the health of the local community. To learn more, visit http://www.duncanfamilyhealthcare.com or call 775.221.7400.
About NeuroStar® Advanced Therapy
NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors, and is widely available across the United States.
NeuroStar is reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.
NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05). The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.
NeuroStar® is a registered trademark of Neuronetics, Inc. For more information and full safety and prescribing information, visit http://www.neurostar.com.